Medical Dermatology
Conference Coverage
Ligelizumab outperformed omalizumab for refractory chronic spontaneous urticaria
PARIS – Investigational drug ligelizumab achieved a faster response, higher clearance rate in a phase 2b study.
Conference Coverage
Secukinumab shows promise in hidradenitis suppurativa
PARIS – Strong efficacy in a pilot study underscores the importance of the Th17 pathway in the pathogenesis of this disease.
News
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
Conference Coverage
Experience – not evidence – is best guide in keloid treatment
LAS VEGAS – Surgery is usually not an option, and it may be necessary to convince patients about other treatment options.
Conference Coverage
Investigational agent VT-1161 looks promising for onychomycosis
LAS VEGAS – The oral agent has potent activity against several species of tinea and yeast.
Conference Coverage
Delusional infestation: not so rare
PARIS – Mayo Clinic study shows prevalence climbs sharply with advancing age.
Conference Coverage
Leflunomide-hydroxychloroquine combo shows promise in primary Sjögren’s pilot study
CHICAGO – Randomized, placebo-controlled trial may support evidence for an added benefit of the two drugs together.
Conference Coverage
Serlopitant quells prurigo nodularis in phase 2 study
PARIS – Multiple phase 3 trials are underway for this promising agent.
Conference Coverage
SLE low-disease definition receives prospective validation
CHICAGO – Researchers validated a proposed definition of low disease activity state in lupus patients in a large, prospective, multicenter study...
Make the Diagnosis
November 2018
A healthy 70-year-old white male presented with a verrucous lesion on his left nose for several months.
From the Journals
Review finds some therapies show promise in managing prurigo nodularis
Among the most positive outcomes were those associated with newer treatments, including those targeting IL-31 signaling.